AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/20/21

An interim analysis of Aurinia Pharmaceuticals' (AUPH) LUPKYNIS (voclosporin) for lupus sustained meaningful reductions in proteinuria with no change in mean estimated glomerular filtration rate at 104 weeks of treatment.The analysis of 216 blinded subjects found that proteinuria co...

- Individuals treated with LUPKYNIS sustained meaningful reductions in proteinuria with no change in mean eGFR at 104 weeks of treatment - - These data, the longest-available outcomes data with LUPKYNIS for the treatment of lupus nephritis to-date, will be presented at Europea...

Biotech stocks are officially in a slump. After a rip-roaring 2020 fueled by the advent of COVID-19 vaccines and therapeutics, the iShares Nasdaq Biotechnology ETF has now lost 10% of its value in the past three months. The industry has suddenly lost favor with investors because of ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in two upcoming investor conferences: RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at ...

– Company-sponsored program seeks proposals to help patients in the U.S. make informed health choices and support underserved populations with these conditions – – Submission process opens on World Lupus Day, Monday May 10, deadline to submit proposa...

The Lancet has published the results of Aurinia Pharmaceuticals' (AUPH) Phase 3 AURORA 1 study evaluating Lupkunis (voclosporin) in adults with lupus nephritis ((LN)). AURORA 1 met its primary endpoint, achieving statistically superior complete renal response rates of 41% in the Lupkynis...

Study results demonstrate that LUPKYNIS in combination with typical standard of care (SoC) led to statistically superior complete renal response rates compared to treatment with SoC alone Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or ...

Aurinia Pharmaceuticals ([[AUPH]] -18.2%) has plunged after the company’s Q1 financials came below expectations.Weighing on the results, Cantor Fitzgerald has maintained the overweight rating and the price target of $34.00 per share which indicates an upside of ~175.5% to the...

Gainers: InnSuites Hospitality Trust (IHT) +95%.Regional Health Properties (RHE) +30%.Cooper-Standard (CPS) +25%.MoneyGram International (MGI) +23%.Epizyme (EPZM) +21%.The L.S. Starrett (SCX) +21%.Clene (CLNN) +20%.Yield10 Bioscience (YTEN) +20%.Phio Pharmaceuticals (PHIO) +19%.Core...

Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aur...